Seegene establishes French subsidiary to expand European footprint
The new subsidiary is expected to accelerate broader adoption of Seegene’s developing solutions, CURECA™ and STAgora™, in Europe
15 Dec 2025
Seegene, Inc. has announced the establishment of a new subsidiary in France to reinforce its European presence and support global sales expansion. The new subsidiary will strengthen local engagement with customers and partners through enhanced technical support, market development and collaboration with healthcare stakeholders.
The subsidiary also provides a strategic foothold for the European rollout of Seegene’s solutions that are in development, CURECA™, a fully automated, unmanned PCR system, and STAgora™, a real-time diagnostic data analytics and predictive insights platform*.
According to global market research firm Grand View Research, Inc., France’s MDx market is estimated to reach approximately EUR 600 million, accounting for around 15 percent of Europe’s total. It is the second-largest market in the region after Germany, which holds a 19 percent share.
Demand in France is particularly high for diagnostic tests targeting sexually transmitted infections (STIs), gastrointestinal (GI) tract infections, and respiratory infections. Through its subsidiary, Seegene aims to expand sales of these product lines while introducing a broader portfolio including cervical cancer and other multiplex diagnostic categories.
“On the French market, which is divided between the private and public sectors, the ability to quickly deliver innovative products and meet laboratories’ efficiency needs is a key factor for competitiveness,” said Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer at Seegene.
“The subsidiary will enable Seegene to gain a better understanding the French healthcare landscape, strengthening local customer service, and accelerate the growth of the company’s in vitro diagnostics business with dedicated local expertise,” he added.
The addition of France brings Seegene’s overseas sales subsidiaries to eight, complementing its global distribution network of 90 distributors across 94 countries.
*CURECA™ and STAgora™ are under development and not available for diagnostic use.